Rapid induction of uterine endometrial proliferative lesions in transgenic mice carrying a human prototype c-Ha- ras gene (rasH2 mice) given a single intraperitoneal injection of N-ethyl- N-nitrosourea
In our previous study, uterine endometrial stromal sarcomas and atypical hyperplasias of the endometrial glands were induced in heterozygous p53 deficient mice (p53 (+/−) mice) of the CBA strain given a single dose of N-ethyl- N-nitrosourea (ENU). In order to clarify whether uterine tumors can be in...
Gespeichert in:
Veröffentlicht in: | Cancer letters 2002-12, Vol.188 (1), p.39-46 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | In our previous study, uterine endometrial stromal sarcomas and atypical hyperplasias of the endometrial glands were induced in heterozygous p53 deficient mice (p53 (+/−) mice) of the CBA strain given a single dose of
N-ethyl-
N-nitrosourea (ENU). In order to clarify whether uterine tumors can be induced in transgenic mice carrying a human prototype c-Ha-
ras gene (rasH2 mice) that are very susceptible to genotoxic carcinogens, rasH2 mice and their wild-type littermates received an intraperitoneal injection of 120 or 0
mg/kg body weight of ENU followed by no further treatment for 22 weeks. Eighteen and 94% of ENU-treated rasH2 mice had uterine endometrial adenocarcinomas and atypical hyperplasias, respectively. Other malignant and benign tumors such as lung alveolar/bronchiolar adenomas and carcinomas, forestomach squamous cell papillomas and carcinomas, splenic hemangiomas/sarcomas, skin papillomas, malignant lymphomas and harderian gland adenomas were also observed in ENU-treated rasH2 mice. The result in the present study suggests that female rasH2 mice are very susceptible to uterine carcinogenesis, providing a useful model for ENU-induced uterine epithelial tumors. |
---|---|
ISSN: | 0304-3835 1872-7980 |
DOI: | 10.1016/S0304-3835(02)00158-1 |